HPS Pharmacies wish to advise that Novo Nordisk is continuing to experience a supply interruption for Ozempic® as follows:
Ozempic® 0.25/0.5mg Pen
Ozempic® 1mg Pen
Supplies of Ozempic® are currently limited due to an unexpected increase in demand. Normal supplies are expected to return by end-December 2022. An internationally registered brand of semaglutide 0.25/0.5mg pens and semaglutide 1mg pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
A statement is available on the Therapeutic Goods Administration (TGA) website reminding health professionals to prioritise the supply of semaglutide for patients with type 2 diabetes.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates